CBER Isolagen Therapy (IT) BLA 125348 FDA Clinical Review Agnes Lim, MD Yao-Yao Zhu, MD, PhD DCEPT/OCTGT/CBER, FDA October 9, 2009 Advisory Committee Meeting.

Slides:



Advertisements
Similar presentations
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Advertisements

Conductive Keratoplasty for the Treatment of Presbyopic Emmetropes and Hyperopes to Improve Near Vision FDA Clinical Trial Protocol RCS-0110PRS 24 Month.
Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.
Modified Megestrol The Clinical Trials by : Carolina R. Akib
1 Efficacy of Testosterone Transdermal System (TTS) for Treatment of HSDD in Surgically Menopausal Women on Concomitant Estrogen Daniel Davis, MD, MPH.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
1 Cellular, Tissue and Gene Therapies Advisory Committee Meeting azfibrocel-T (previously Isolagen Therapy (IT)) BLA Proposed Indication: Treatment.
Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.
Targeting Tumors Using Endogenous Albumin
A randomized, double-blind study on MD-knee versus HA in patients affected by knee OA: preliminary data from the JOINT study Umberto Massafra Dep of Rheumatology,
12/10/02Harry Bushar1 Computerized Thermal Imaging Breast Cancer System 2100 (CTI BCS2100) Radiological Devices Advisory Panel December 10, 2002 Statistical.
Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.
Overview of the Clinical Trial & Protocol Jane Fendl March 31, 2010
1 Session 3 Basic Results Database Deborah A. Zarin, M.D. Background Specific Results Data Elements Data Entry and Display Mockups.
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.
1 Statistical Perspective Acamprosate Experience Sue-Jane Wang, Ph.D. Statistics Leader Alcoholism Treatment Clinical Trials May 10, 2002 Drug Abuse Advisory.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
1 Sex/Gender and Minority Inclusion in NIH Clinical Research What Investigators Need to Know! Presenter: Miriam F. Kelty, PhD, National Institute on Aging,
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
Antidepressants and Suicidality in Adults: Statistical Evaluation Mark Levenson, Ph.D.* and Chris Holland, M.S. Statistical Safety Reviewers Quantitative.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Pulmonary-Allergy Drugs Advisory Committee January 17, FLOVENT ® DISKUS ® NDA , S004 GlaxoSmithKline Pulmonary-Allergy Drugs Advisory Committee.
Lessons Learned from Opioid Addiction Trials
DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.
Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.
1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.
Laser-Ranibizumab-Triamcinolone for DME Study DRCR.net Protocol I
ACAMPROSATE Efficacy Results from Three Pivotal Efficacy Trials Karl F. Mann, M.D. Professor and Chairman Director, Department of Addictive Behavior and.
Statistical Review of Intergel by Richard Kotz Statistician, CDRH/OSB.
1 1 Zelnorm ® (tegaserod maleate) Advisory Committee Presentation Gastrointestinal Drugs July 14, 2004.
Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
Vaccines and Related Biological Products Advisory Committee Meeting Hepatitis B Vaccine (Recombinant), Adjuvanted (HEPLISAV): Review of Immunogenicity.
How to Start An Industry Sponsored Clinical Trial
General and Plastic Surgery Devices Panel
The Effect of Bimatoprost 0.03% vs Travoprost 0.004% in Patients on Latanoprost 0.005% Requiring Additional IOP Lowering Jeffrey A. Kammer, 1 Barry Katzman,
Predictors of study retention in addiction treatment trials KORTE JE 1, MAGRUDER KM 1,2, KILLEEN TK 1, SONNE SC 1, SAMPSON RR 1 and BRADY KT 1,2 1. Medical.
Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.
1 BLA Sipuleucel-T (APC-8015) FDA Statistical Review and Findings Bo-Guang Zhen, PhD Statistical Reviewer, OBE, CBER March 29, 2007 Cellular, Tissue.
SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
Augmentation of Exposure-Based Cognitive Behavioral Therapy with D-cycloserine in Patients with Panic Disorder Sean Donovan, Meenakshi Shelat, Corrinne.
Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.
SNDA # GLIADEL® WAFER (Polifeprosan 20 with Carmustine Implant) APPLICANT: GUILFORD PHARMACEUTICALS ODAC: December 6, 2001 Medical Reviewer: Alla.
1 NDA Clofarabine Cl-F-Ara-A Presented by Martin Cohen, M.D. at the December 01, 2004 meeting of the Oncologic Drugs Advisory Committee meeting.
YOU CAN DISCOVER YOUR HIDDEN BEAUTY
Macugen (pegaptanib sodium injection) Advisory Committee Meeting August 27, 2004 Jennifer D. Harris, MD Medical Officer Division of Anti-Inflammatory,
Safety, Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines: The Phase 2 BELMONT Study Authors:
1 Clinical Studies Section of Labeling Joseph Porres, M.D., Ph.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA.
Omadacycline in Acute Skin and Skin Structure Infections Study (OASIS) A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and.
Treatment-Naïve Adults
Switch to INSTI + NNRTI Switch to DTG + RPV SWORD Study
Supplemental Figure S1 (A) (B) Any Statin ↓Randomisation
Clinicaltrials.gov Update
Protocol U Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involved DME Following Anti-VEGF.
Thadhani et al. Am J Nephrol 2017;45:40-48  (DOI: / )
PCSK9 Inhibitors Post-CVOTs
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
Engagement Survey Results: Demographics
Short-Term Evaluation of Combination
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30mg and ibuprofen 2400mg for the treatment of patients with osteoarthritis 
Switch to INSTI + NNRTI Switch to DTG + RPV SWORD Study
Design Randomisation * 2 : 1 Double blind W12 W16 W24 W28
Alan Menter, MD, Stephen K
Safety and Efficacy of Mapracorat Ophthalmic Suspension in the Treatment of Inflammation Following Cataract Surgery: Adaptive Design Study Timothy L.
How Should We Select and Define Trial Estimands
Presentation transcript:

CBER Isolagen Therapy (IT) BLA FDA Clinical Review Agnes Lim, MD Yao-Yao Zhu, MD, PhD DCEPT/OCTGT/CBER, FDA October 9, 2009 Advisory Committee Meeting

CBER Presentation Outline Overview of Pivotal Studies  Studies IT-R-005 and IT-R-006 Study Results  Efficacy Results  Safety Results

CBER Overview of Pivotal Studies IT-R-005 and IT-R-006 Proposed indication  Treatment of moderate to severe nasolabial fold wrinkles in adults Title: A Phase 3, Multicenter, Double- Blind, Randomized, Placebo- Controlled Trial of the Efficacy and Safety of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles

CBER IT Administration Dosage: Dosage: 0.1 mL/linear cm, up to 2 mL/Tx ( x 10 7 cells/mL) Three treatment visits, at intervals of 5 ± 1 week Control: vehicle-medium only

CBER Subject Wrinkle Assessment “ How do you feel about the wrinkles in the lower part of your face today”? -2 Very Dissatisfied - 1Dissatisfied 0 Somewhat Satisfied 0 Somewhat Satisfied +1 Satisfied +2 Very Satisfied

CBER Evaluator Wrinkle Severity Assessment (Lemperle) with Photoguide Grade 0 No wrinkle Grade 1 Just perceptible Grade 2 Shallow Grade 3 Moderately deep Grade 4 Deep, well defined edge Grade 5 Very deep, redundant fold

CBER Key Eligibility Criteria IT-R-005 and IT-R-006 Inclusion  M or F ≥ 18 years old  Pre-specified nasolabial fold wrinkle gradings of moderate/severe by both subjects and evaluators  Post-auricular skin acceptable for biopsy Exclusion  Total treatment area > 20 cm in length  Pre-specified skin conditions  Pre-specified previous facial cosmetic procedures, dermal fillers or Rx  Basal cell carcinoma

CBER Treatment Schema Efficacy evaluation at 6 months following last treatment injection (Visit 6) Co-primary efficacy endpoints: Subject Wrinkle Assessment Evaluator Wrinkle Severity Assessment Safety assessment every visit; Final safety assessment by telephone at 12 month 1. Severity ≥ Grade 3 of bilateral nasolabial fold wrinkles by evaluator 2. Subjects Dissatisfied or Very Dissatisfied with appearance of wrinkles in lower face 3. Met entrance criteria Skin biopsy/Baseline; biopsy meet acceptance criteria; randomized by site IT, n= 100 Up to 2mL (1-2x10 7 cells/mL) / Tx Every 5 ± 1 wk Total 3 treatments Vehicle-control, n = 100 Every 5 ± 1 wk Total 3 treatments

CBER Primary Efficacy Endpoints Co-primary Endpoints Wrinkle Assessment at Baseline Success at 6 month Evaluator Wrinkle Severity Assessment Grade >3 2-point or better improvement for both sides Subject Wrinkle Assessment -1: dissatisfied -2: very dissatisfied 2-point or better improvement

CBER Secondary Endpoints Wrinkle Assessment at Baseline Success at Visits 3,4,5 Evaluator Wrinkle Severity Assessment Grade >3 2-point or better improvement on both sides Subject Wrinkle Assessment -1: dissatisfied -2: very dissatisfied 2-point or better improvement

CBER Secondary Endpoints (cont.) Photos at Baseline versus Photos at Visits 3,4,5,6 Subject Improvement Assessment Scale used for rating wrinkle/appearance on photos: -2= much worse than before -1= worse than before 0= the same as before +1= better than before +2= much better than before Evaluator Improvement Assessment

CBER Statistical Plan Analysis populations:  ITT = all randomized  MITT =  MITT = received ≥ one treatment  EE (Efficacy Evaluable) = met entrance criteria, received all 3 treatments, and no major protocol violation 80% power at a two-sided significance level of 0.05   Response rates > 40% of IT;  20% for vehicle- control Missing data imputed as treatment failures

CBER IT-R-005 and IT-R-006 Study Results

CBER IT-R-005 and IT-R-006 Enrollment Study ITControl # of Sites Study Period IT-R-005n= /06-06/08 IT-R-006n= /06-06/08

CBER Demographics of ITT Population Population Categories IT-R-005IT-R-006 ITn=100Controln=103ITn=110Controln=108 Ages (Years) Mean (SD) Median Range 57.5 (8.3) (7.9) (10.4) (9.9) Age Groups n (%) < 50 > 50, < 65 > (19%) 60 (60%) 21 (21%) 25 (24%) 62 (60%) 16 (16%) 39 (35%) 56 (51%) 15 (14%) 34 (31%) 55 (51%) 19 (18%) Gender n (%) Female Male 88 (88%) 12 (12%) 94 (91%) 9 (9%) 103 (94%) 7 (6%) 95 (88%) 13 (12%) Race n (%) White Black or African-American Asian American Indian or Alaska Others 94 (94%) 1 (1%) 2 (2%) 0 3 (3%) 99 (96%) 2 (2%) 0 1 (1%) 98 (89%) 1 (1%) (10%) 95 (88%) 1 (1%) (11%) Ethnicity n (%) Hispanic/Latino 10 (10%) 7 (7%) 12 (11%)

CBER Key Demographics Demographics similar between studies IT-R-005 and IT-R-006 Age: Median 56 years old; range Gender: 90% Female Race: 92% White 92% White 1% Black/African-American 1% Black/African-American 1% Asian 1% Asian Ethnicity: 10% Hispanic/Latino

CBER Disposition of Subjects IT-R-005IT-R-006Total ITn=100Controln=103ITn=110Controln=108 n=421 Study Completion Status: Completed Study Completed Study Early Termination Early Termination 80 (80%) 20 (20%) 88 (85%) 15 (15%) 93 (85%) 17 (15%) 98 (91%) 10 (9%) 359 (85%) 62 (15%) Reasons for Early Termination: Subject Withdrawal Subject Withdrawal Sponsor Request Sponsor Request Adverse Event Adverse Event Protocol Non-Compliance Protocol Non-Compliance Lost to Follow-Up Lost to Follow-Up Others Others 7 (7%) 5 (5%) 1 (<1%) 3 (3%) 1 (1%) 3 (3%) 6(6%) 1 (<1%) 3 (3%) 10 (9%) 1 (<1%) 2 (2%) 0 1 (<1%) 4 (4%) 1 (<1%) (5%) 4 (<1%) 7 (2%) 4 (<1%) 7 (2%)

CBER Manufacturing Failure The total IT manufacturing failure in the two pivotal studies was 11% (24/210) IT/Control pairing to maintain randomization/study blind for re-biopsies due to manufacturing failures Type of Failure IT-R-005N=203IT-R-006N=218 ITn=100Controln=103ITn=110Controln=108 No product produced, Total 5 (5%) 1 (1%) 8 (7%) 4 (4%) Insufficient product, Total: 3 (3%) 0 8 (7%) 1 (1%) 1 Tx received 1 Tx received 1 (1%) 0 4 (4%) 0 2 Tx received 2 Tx received 2 (2%) 0 4 (4%) 1 (1%)

CBER Primary Endpoints Success Rate at 6 Month Co-Primary Endpoints IT-R-005N=203IT-R-006N=218 ITn=100Controln=103p-valueITn=110Controln=108p-value Evaluator Wrinkle Severity Assessment 33(33%)7(7%)< (19%)8(7%) Subject Wrinkle Assessment 57(57%)31(30%) (45%)19(18%)<0.0001

CBER Efficacy Conclusions Both co-primary endpoints at six months were met in each of the pivotal studies Results of secondary endpoints supportive of primary efficacy results Efficacy of IT > 6 months has not been demonstrated No studies conducted for effects of repeating treatment cycles

CBER Safety Results

CBER Safety Overview Safety database Commercial experience Safety Population IT Vehicle- Control Total IT-R-005 & clinical trials (integrated safety population)

CBER Safety Monitoring Schedule in 005 & 006 Safety Monitoring Schedule in 005 & wks 5 wks 8 wks 8 wks 8 wks 28 wks Total Safety Observation Period : 62 weeks Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Telephone Call Treatment Visits * Acute Study: Visits 1, 2, 3, 4, 5, & 6: 34 weeks * Long-Term Study: a telephone call at 12 months from Visit 3

CBER Adverse Events in IT-R-005 > 1% Preferred Terms Preferred Terms IT N=83 Control N=92 SubjectsEventsSubjectsEvents All treatment-emergent AE 51 (61%) (62%) 219 Administration site conditions Administration site conditions 31 (37%) (35%) 94 (Related to Treatment) (Related to Treatment) 28 (33%) (26%) 76 Injection-site erythema Injection-site erythema 23 (28%) (19%) 28 Injection-site swelling Injection-site swelling 18 (22%) (16%) 27 Injection-site pain Injection-site pain 5 (6%) 6 4 (4%) 5 Injection-site bruising Injection-site bruising 4 (5%) 5 12 (13%) 17 Injection-site nodules Injection-site nodules 2 (2%) 3 2 Injection-site reaction Injection-site reaction 2 (2%) 2 2 Injection-site papules Injection-site papules 2 (2%) 2 1 (1%) 1

CBER Adverse Events in IT-R-006 > 1% Preferred Terms Preferred Terms IT n=98 Control n=99 SubjectsEventsSubjectsEvents All treatment-emergent AE 62 (63%) (57%) 172 Administration site conditions 32 (33%) (32%) 84 (Related to Treatment) (Related to Treatment) 29 (30%) (31%) 80 Injection-site erythema Injection-site erythema 14 (14%) 19 6 (6%) 9 Injection-site hemorrhage Injection-site hemorrhage 10 (10%) (15%) 45 Injection-site bruising Injection-site bruising 5 (5%) 6 13 (13%) 20 Injection-site papules Injection-site papules 4 (4%) 4 2 (2%) 2 Injection-site irritation Injection-site irritation 3 (3%) 6 1 (1%) 3 Injection-site swelling Injection-site swelling 3 (3%) 300

CBER Related-Adverse Events < 1% in IT-R-005 & 006 StudyGroup Preferred Terms Onset from treatment DurationSeverityAction 005IT Basal cell cancer 7 months after 1 st n/amoderateexcision 005IT Herpes simplex of lip 5 days after 1 st 4 days mildmeds 005IT Post-procedural headache On 2 rd treatment 2 days mildmeds 005Control Swelling under left eye 2 days after 1 st 5 days mildnone 005ControlHeadache On 1 st treatment 1 day moderatemeds 005Control Injection site anesthesia 3.5 months after 3 rd 5.5 months mildnone 005Control Pain in jaw On 1 st treatment 2 days mildnone 005Control Paraesthesia right upper lip 2 days after 1 st 3 days mildnone 005Control Post-procedural discomfort On 1 st treatment 1 day mildnone 006IT Bilateral eyelid edema 1 day after each of 3 treatments 1 st, 2 rd : 1 week 3 rd : > 1 year mildnone 006IT Skin hyperpigmentation 1 day after 2 rd 3 weeks mildnone 006Control Injection site hypersensitivity On 1 st treatment 2 days moderatenone

CBER Basal Cell Carcinoma 76 y.o. white female with “sun damage” Three IT treatments in IT-R-005 Detection time: 7 months after first injection Right upper lip near nasolabial fold, tumor: 0.4 cm x 0.4 cm; solar keratosis was found at bridge of nose Possibly related per investigator Intervention: biopsy and Mohs Excision Other AEs: erythema and swelling for 3 days Wrinkle outcome: non-responder per investigator Most recent f/u: no evidence of recurrence 18 months after the surgery

CBER Integrated Safety Data in 7 trials StudyPhases Safety Observation (Months)SubjectsIT/ControlTreatmentInterval(Weeks)Indications IT-R-001 Phase /101-2 Rhytids and scars (14 facial areas) IT-R-002 Phase /401-2 Rhytids and scars (14 facial areas) IT-R-003A Phase /591-2 Nasolabial and glabellar (4 areas) IT-R-003B Phase /541-2 Nasolabial and glabellar (4 areas) IT-R-005Pivotal1583/924-6 Nasolabial (2 areas) IT-R-006Pivotal1598/994-6 IT-R-007 Phase /04-6 Forehead, periorbital, cheek, perioral (8 areas) Total (467/354) (injected areas)

CBER Injection-Site Reactions (> 1%) Preferred Terms Preferred Terms IT (N=508) Control (N=354) Administration Site Conditions 343 (67%) 144 (40%) (Related to Treatment) (Related to Treatment) 265/508 (52%) 119/354 (34%) Injection-site erythema Injection-site erythema 81 (16%) 33 (9%) Injection-site bruising Injection-site bruising 54 (11%) 48 (14%) Injection-site swelling Injection-site swelling 69 (14%) 15 (4%) Injection-site pain Injection-site pain31(6%) 6 (2%) Injection-site edema Injection-site edema 22 (4%) 0 Injection-site nodules Injection-site nodules 20 (4%) 3 (<1%) Injection-site hemorrhage Injection-site hemorrhage 13 (3%) 16 (5%) Injection-site papules Injection-site papules 8 (2%) 3(<1%) Injection-site irritation Injection-site irritation 6 (1%) 1 (<1%) Injection-site dermatitis Injection-site dermatitis 5 (1%) 2 (<1%) Injection-site pruritus Injection-site pruritus 5 (1%) 3 (<1%) Injection-site reactions Injection-site reactions 5 (1%) 2 (<1%) Injection-site indurations Injection-site indurations 5 (1%) 0

CBER Total Injection Site Reactions in Pivotal Trials and Integrated Safety Population>1% StudyIT-R-005IT-R-006 Integrated safety population SubjectsITN=83 Control N=92 ITN=98 Control N=99 ITN=508ControlN=354 Administration Site Conditions 31 (37%) 32 (35%) 32 (33%) 32 (32%) 343 (67%) 144 (40%) Higher frequency of injection site adverse events in integrated safety population Lower frequency of injection site adverse events in 005 & 006 Reasons for the decreased injection site adverse events Increased treatment intervals, decreased treatment areas, enhanced physician training for injection Increased spacing for clinical safety observation intervals

CBER Related-Adverse Events < 1% (ISP) Related-Adverse Events < 1% (ISP) Preferred Terms IT N=508 Control N=354 Acne40 Rash20 Eye edema 21 Face edema 31 Herpes labialis 30 Injection site vesicles 10 Hypoaesthesia20 Injection site hypersensitivity 01 Lip paraesthesia 01 Basal cell carcinoma 10 Injection site fibrosis 10 Injection site ischemia 20 Parapsoriasis10 Alopecia areata 10 Hyperpigmentation10 Pain in jaw 01 Headache52 Post-procedural discomfort 01 Toothache01 Chapped lips 10 Dizziness20 Total329

CBER Severity of Injection-Site Adverse Events >1% Administration-site conditions IT N=343 Control N=144 Mild 283 (82.5 %) 131 (91%) Moderate 55 (16%) 12 (8%) Severe 5 (1.5%) 1 (<1%) N=subjects reporting injection site adverse events Severity grading: CTCAE V3 (NCI/NIH) 6 cases of severe injection-site adverse events 5 IT subjects: erythema (1), ischemia (1), swelling (2), pain (1) 1 control subject: bruising Resolved within 10 days, no withdrawal

CBER Duration of Related-Adverse Reaction>1% AE Duration in Days IT: related events = 444 Control: related events = 207 <1 to (85.5%) 187(90%) 8 to (5%) 13 (6%) 15 to (3.6%) 1 (0.5%) 31 to 60 9 (2%) 2 (1%) 61 to 90 8 (1.8%) 2 (1%) 91 to (0.4%) 0 Ongoing 5 (1%) 0

CBER Unresolved Adverse Events (All Subjects in IT Group) Study Adverse Events Treatment Areas Onset Day Duration in Day SeverityAction IT-R- 001 Red,swelling in glabellar Glabellar,perio ral 2ndtreatment357+mild Benadryl Aleve IT-R- 002 Flare of alopecia areata Nasolabial, perioral Third day from 2nd treatment 354+mild Aldara, Kenalog IT-R- 003A Plumpness in upper lip Nasolabial, glabellar A month from 3rd treatment 287+mildno IT-R- 005 Ridge in right nasolabial fold nasolabial A week from 2 nd treatment 409+mildno IT-R- 006 Swelling on both upper eye lids nasolabial Third treatment 396+mildno

CBERSubgroups Under-represented subgroups in integrated safety population Safety profiles –Similar common injection-site reactions –No keloid formation reported –Limited information due to small sample sizes Sub-groupsITN=467* Control N=354 TotalN=821 >65 yo 44 (9%) 41 (12%) 85 (10%) Male 42 (9%) 34 (10%) 76 (9%) Non-white 43 (9%) 35 (10%) 78 (10%) * 41 cross-over subjects not included

CBER Commercial Experience US: 1,200 + subjects ( ) UK: 7,800 + subjects ( ) Retrospective chart reviews, limited registry Common AEs: red, swelling, rash, lump Three serious adverse event reports –Angioedema –Severe systemic allergic reaction –Lump on the eyelid, requiring surgery

CBER Safety Summary Adverse events in >1% injection site redness, bruising, swelling, pain, nodules, hemorrhage, papules, irritation, dermatitis, pruritus Adverse events in <1% Probable facial allergic reactions, flare of herpes labialis, change of skin sensation, post-procedural discomfort Severity and duration of adverse reactions Mild/moderate in severity 5% injection-site events lasting beyond 30 days Five cases unresolved beyond one year One case of injection-site basal cell cancer Two cases of serious allergic reactions in UK Small sample sizes for male, elderly, and non-white Safety observation limited to 12 to 15 months

CBER THANK YOU